{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:02:15Z","timestamp":1776276135498,"version":"3.50.1"},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,10,1]]},"DOI":"10.2169\/internalmedicine.3071-23","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T22:16:14Z","timestamp":1709504174000},"page":"2631-2636","source":"Crossref","is-referenced-by-count":5,"title":["Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab"],"prefix":"10.2169","volume":"63","author":[{"given":"Shinji","family":"Unome","sequence":"first","affiliation":[{"name":"Department of Gastroenterology\/Internal Medicine, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology\/Internal Medicine, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Miwa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology\/Internal Medicine, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology\/Internal Medicine, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Suetsugu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology\/Internal Medicine, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology\/Internal Medicine, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Suzui","sequence":"additional","affiliation":[{"name":"Department of Pathology, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology\/Internal Medicine, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249, 2021.","DOI":"10.3322\/caac.21660"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68: 113-126, 2018.","DOI":"10.1002\/hep.29789"},{"key":"3","unstructured":"3. World Health Organ Classification Tumours Editorial Board. Digestive system tumours. In: WHO Classification Tumours. 5th ed. International Agency for Research on cancer, Lyon, 2019: 215-263."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kim KH, Lee SG, Park EH, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol 16: 623-629, 2009.","DOI":"10.1245\/s10434-008-0278-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kobayashi S, Terashima T, Shiba S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 109: 2549-2557, 2018.","DOI":"10.1111\/cas.13656"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Salimon M, Prieux-Klotz C, Tougeron D, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer 118: 325-330, 2018.","DOI":"10.1038\/bjc.2017.413"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Trikalinos NA, Zhou A, Doyle MBM, et al. Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience. J Natl Compr Canc Netw 16: 1193-1199, 2018.","DOI":"10.6004\/jnccn.2018.7053"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rizell M, \u00c5berg F, Perman M, et al. Checkpoint inhibition causing complete remission of metastatic combined hepatocellular-cholangiocarcinoma after hepatic resection. Case Rep Oncol 13: 478-484, 2020.","DOI":"10.1159\/000507320"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kim EJ, Yoo C, Kang HJ, et al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int 41: 1398-1408, 2021.","DOI":"10.1111\/liv.14813"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gigante E, Hobeika C, Le Bail B, et al. Systemic treatments with tyrosine kinase inhibitor and platinum-based chemotherapy in patients with unresectable or metastatic hepatocholangiocarcinoma. Liver Cancer 11: 460-473, 2022.","DOI":"10.1159\/000525488"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Osuga T, Miyanishi K, Ito R, et al. A case of unresectable combined hepatocellular-cholangiocarcinoma successfully treated with lenvatinib. Case Rep Oncol 15: 318-325, 2022.","DOI":"10.1159\/000523895"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Saito N, Hatanaka T, Nakano S, et al. A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clin Case Rep 10: e6129, 2022.","DOI":"10.1002\/ccr3.6129"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Pomej K, Balcar L, Shmanko K, et al. Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma - a European multicenter cohort. ESMO Open 8: 100783, 2023.","DOI":"10.1016\/j.esmoop.2023.100783"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1: EVIDoa2100070, 2022.","DOI":"10.1056\/EVIDoa2100070"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1: EVIDoa2200015, 2022.","DOI":"10.1056\/EVIDoa2200015"},{"key":"16","unstructured":"16. Brierley JD, Gospodarowicz MK, Wittekind Ch. TNM Classification of Malignant Tumours. 8th ed. Chichester. John Wiley & Sons, Inc., West Sussex, UK; Hoboken, NJ, 2017: 80-84."},{"key":"17","unstructured":"17. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [Internet]. U.S. U.S. Department of Health and Human Services; 2017 Nov 27 [cited 2023 Dec 18]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol 30: 385-396, 2019.","DOI":"10.1093\/annonc\/mdz003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 49: 1109-1113, 2019.","DOI":"10.1111\/hepr.13411"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Na SK, Choi GH, Lee HC, et al. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. PLOS ONE 13: e0198138, 2018.","DOI":"10.1371\/journal.pone.0198138"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382: 1894-1905, 2020.","DOI":"10.1056\/NEJMoa1915745"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Satake T, Shibuki T, Watanabe K, et al. Case Report: atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma. Front Oncol 13: 1234113, 2023.","DOI":"10.3389\/fonc.2023.1234113"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nguyen CT, Caruso S, Maille P, et al. Immune profiling of combined hepatocellular- cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. Clin Cancer Res 28: 540-551, 2022.","DOI":"10.1158\/1078-0432.CCR-21-1219"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37: 318-327, 2019.","DOI":"10.1200\/JCO.2018.78.2276"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21: 796-807, 2020.","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56: 2188-2205, 2023.","DOI":"10.1016\/j.immuni.2023.09.011"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78: 1922-1965, 2023.","DOI":"10.1097\/HEP.0000000000000466"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/19\/63_3071-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T03:32:33Z","timestamp":1728099153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/19\/63_3071-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":27,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3071-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"article-number":"3071-23"}}